Please login to the form below
3
Revenue 2017Roche
The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Roche's 2013 sales performance.
Roche’s Herceptin/Perjeta fixed-dose combo filed with FDA
Final decision due by 18 October. A fixed-dose combination of Roche’s HER2 drugs Herceptin and Perjeta has started a review at the FDA, with a decision due by 18 ... October. The co-formulation of two of Roche’s blockbuster breast cancer antibodies
Coronavirus outbreak escalation could impact drug supply chain
Other drug makers, including Roche, Merck &Co, Bayer, Johnson &Johnson and Pfizer have all acknowledged that that they are monitoring the situation and potential for the outbreak to affect supply chains.
BMS scores first oesophageal cancer nod for Opdivo in Japan
That includes Keytruda, Roche’s Tecentriq (atezolizumab), AstraZeneca’s Imfinzi (druvalumab) and Sanofi’s latecomer Libtayo (cemiplimab).
GSK pays $50m upfront to tap Immatics’ cell therapy platform
Deal focuses on T cell receptor therapies
Targacept picks Solvay's Stephen Hill to fill vacant CEO post
Prior to that, he served at US biotech ArQule and Roche, where he held several leadership positions including global head of clinical development.
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
Featured jobs
- Digital Associate Director - Medcomms
-
£65000 - £80000 per annum
- Account Director, Healthcare Communications
-
Salary TBC
-
Account Manager (PR)
-
Great Benefits
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
-
Account Manager
-
£Competitive Salary
- Group Director of Medical Affairs and Scientific Strategy, Medic...
-
Substantial six figure package
- Senior Medical Writer, MedComms Agency
-
Salary TBC
-
Scientific Director
-
£60000 - £85000 per annum, Benefits: Bonus, pension, subsidised gym and much more
-
Account Director
-
£Competitive Salary
- Brand Manager - Medium Global Pharma Company
-
£Competitive Financial Package
- Senior Medical Writer or Lead Medical Writer
-
£Competitive Salary
-
Senior External Communications Lead
-
£Competitive Salary
-
Account director
-
Competitive salary and bonus scheme
-
Publications director
-
Competitive salary and bonus scheme
-
Account Director, Medical Education
-
Salary TBC
-
Experienced medical editor
-
Competitive salary and bonus scheme
Subscribe to our email news alerts
- Introducing Nucleus POLAR™, a state-of-the-art external expert search engine and engagement management tool
- Moderna and GSK advance coronavirus vaccine candidates
- FDA accepts review to broaden GSK’s Zejula label
- Sanofi says it will spin out active ingredient business by 2022
- Coronavirus outbreak escalation could impact drug supply chain
- Roche’s Herceptin/Perjeta fixed-dose combo filed with FDA
PMHub
Life Healthcare Communications
Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...
Latest intelligence
- BRIC markets
- Why these countries offer an opportunity for pharma despite a slowdown...
- Obstetrics Virtual Journal Club: An Impetus Digital Customer Success Story
- Our online solutions are not just for advisory boards - find out how one client leveraged the Impetus InSite Platform® for a virtual journal club....
- Novo Nordisk awakens its ‘Sleeping Beauty’
- Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
Quick links
Infographics
